SAN RAMON, Calif., May 19, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed
to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced
that combined safety data from the Company’s GALE-401 clinical trials will be presented at the upcoming European Hematology
Association 21st Congress taking place June 9-12, 2016 in Copenhagen, Denmark. Details of the poster presentation
are as follows:
| Abstract #: |
|
P675 – the abstract can be found on the conference website here
|
| Title: |
|
Anagrelide Controlled Release (GALE-401) Safety Profile Consistently Well Tolerated in Myeloproliferative
Neoplasms Patients and Healthy Volunteers |
| Session Title: |
|
Myeloproliferative Neoplasms - Clinical 2 (Poster) |
| Date: |
|
Saturday, June 11, 2016 |
| Time: |
|
5:30 p.m. to 7:00 p.m. local time |
| Location: |
|
Poster area (Hall H) |
|
|
|
About GALE-401 (Anagrelide Controlled Release)
GALE-401 (Anagrelide Controlled Release) contains the active ingredient anagrelide. The currently available immediate
release formulation (Agrylin® or anagrelide IR) is approved by the FDA for the treatment of patients with thrombocythemia,
secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate
associated symptoms including thrombo-hemorrhagic events. Adverse events associated with anagrelide IR, such as nausea, diarrhea,
abdominal pain, palpitations, tachycardia, and headache, may be dose and plasma concentration dependent. Reducing the maximum
plasma concentration (Cmax) is expected to reduce side effects, but preserve efficacy. GALE-401 is a reformulated,
controlled release version of anagrelide. A Phase 2 pilot study with GALE-401 is ongoing.
About Myeloproliferative Neoplasms
Myeloproliferative neoplasms (MPNs) are a closely related group of hematological malignancies in which the bone marrow cells
that produce the body's blood cells develop and function abnormally. The main MPNs are polycythemia vera (PV), chronic myelogenous
leukemia (CML), primary myelofibrosis (PMF), and essential thrombocythemia (ET), all of which are associated with high platelet
counts. The MPNs are progressive blood cancers that can strike anyone at any age, and for which there is no known cure.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology
therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly
growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The
Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by
NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 breast cancer clinical trial with several
concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a
clinical trial in ovarian and endometrial cancers and in a Phase 1b given sequentially with GALE-302. For more
information, visit www.galenabiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements about the progress of the development of Galena’s product
candidates, patient enrollment in our clinical trials, as well as other statements related to the progress and timing of our
development activities, present or future licensing, collaborative or financing arrangements, expected outcomes with regulatory
agencies, and projected market opportunities for product candidates or that otherwise relate to future periods. These
forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those identified under “Risk
Factors” in Galena’s Annual Report on Form 10-K for the year ended December 31, 2015 and most recent Quarterly Reports on Form 10-Q
filed with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements. Galena does
not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that
occur after the date of this press release.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact: Remy Bernarda SVP, Investor Relations & Corporate Communications (925) 498-7709 ir@galenabiopharma.com
